Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Mult Scler. 2018 May 18;24(8):1014–1022. doi: 10.1177/1352458518775550

Table 1.

Incidence of PML in MS DMTs

DMT Cases of PML PML Patient Age
Natalizumab 763 in >181,300 patientsa 15–73
Fingolimod 19 in >225,000 patientsb* 34–71
Dimethyl Fumarate 5 in >270,000 patientsa* 54–66
Ocrelizumab 0 in >40,000 patientsc*
Teriflunomide 0 in >71,000 patientsd*
Alemtuzumab 0 in >18,400 patientsd*
*

Cases of PML not attributable to prior natalizumab exposure

a

Biogen internal data file,

b

Novartis internal data file,

c

Genentech internal data file,

d

Sanofi Genzyme internal data file.